Merck, EyeBio Begin Phase 2b/3 Trial for Restoret-February 2024-www.financetom.com

Merck, EyeBio Begin Phase 2b/3 Trial for Restoret

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Merck, EyeBio Begin Phase 2b/3 Trial for Restoret

Sep 4, 2024 5:29 AM

07:23 AM EDT, 09/04/2024 (MT Newswires) -- Merck ( MRK ) and subsidiary EyeBio said Wednesday they initiated the phase 2b/3 trial evaluating the investigational therapy Restoret for the treatment of diabetic macular edema.

Diabetic macular edema is an eye condition triggered by diabetes that could lead to blindness.

"Data from the Phase 1/2 AMARONE study provided early evidence for the potential of MK-3000 for patients with retinal disease," EyeBio Chief Executive David Guyer said.

Price: 116.30, Change: -0.28, Percent Change: -0.24

Previous page： Lifeway Foods Shares Jump After Q4 Earnings, Sales Rise Next page： Top Midday Decliners

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Lifeway Foods Shares Jump After Q4 Earnings, Sales Rise

Mar 20, 2024

01:54 PM EDT, 03/20/2024 (MT Newswires) -- Lifeway Foods ( LWAY ) shares jumped more than 15% in recent Wednesday trading after the company reported higher Q4 results. The company reported Q4 earnings of $0.26 per diluted share, up from $0.05 a year earlier. One analyst surveyed by Capital IQ expected $0.21. Net sales for the quarter ended Dec. 31...

Top Midday Decliners

Mar 20, 2024

01:53 PM EDT, 03/20/2024 (MT Newswires) -- Lifecore Biomedical ( LFCR ) said Wednesday it has decided to continue with its standalone strategic plan after evaluating various alternatives, including reviewing more than 75 potential buyers. The company also named Paul Josephs its next president and chief executive officer, effective May 20. Shares slumped 32%, with intraday trading volume at over...

--Worthington Industries Keeps Quarterly Dividend at $0.16 a Share, Payable June 28 to Shareholders of Record June 14

Mar 20, 2024

01:48 PM EDT, 03/20/2024 (MT Newswires) -- Price: 63.14, Change: +0.25, Percent Change: +0.40 ...

Synopsys has narrowed suitors for security unit to half dozen, CEO says

Mar 20, 2024

SANTA CLARA, California, March 20 (Reuters) - Synopsys ( SNPS ) Chief Executive Sassine Ghazi on Wednesday said the company has narrowed potential suitors for its security software unit down to about a half dozen. Synopsys ( SNPS ) said last year it will sell off the unit, which Bloomberg has reported could be valued at $3 billion. At the...